Large scale analytics for electronic health records: Lessons from Observational Health Data Science and Informatics (OHDSI)

Similar documents
Patrick Ryan, PhD Janssen Research and Development Columbia University Medical Center 12 July 2017

The journey toward Clinical Characterization. Patrick Ryan, PhD Janssen Research and Development Columbia University Medical Center

OHDSI: Drawing reproducible conclusions from observational clinical data

Results from OHDSI and perspectives for international data sharing projects

Methodologies for CRNs: Can Statisticians, Epidemiologists, and Machine Learners Play in the Same Sand Box? Perspectives from OHDSI

Applying Hill's criteria as a framework for causal inference in observational data

ObservaBonal research results in literature

The journey toward Population-level Effect Estimation. Martijn Schuemie, PhD Janssen Research and Development

Reliable and reproducible effect size estimates at scale

EMR Big Data and Clinical Research. -Distributed Research Network and Common Data Model-

Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data

Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data

Supplementary Online Content

Using negative control outcomes to identify biased study design: A self-controlled case series example. James Weaver 1,2.

Supplementary figures and tables. Figure A: Study schematic

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

Antidepressant Selection in Primary Care

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Antidepressant Selection in Primary Care

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

Mood Disorders.

A Retrospective Claims Analysis of Medication Adherence and. Persistence Among Patients Taking Antidepressants

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Disclaimer. The following report contains a description of the request, request specifications, and results from the modular program run(s).

Before you try another medication, try asking your DNA

Supplementary Online Content

Meta Analysis for Safety: Context and Examples at US FDA

OHDSI Tutorial: Design and implementation of a comparative cohort study in observational healthcare data

What are you trying to achieve? Falls Prevention, Assessment and Management Strategies. Falls can be classified into four main groups:

Depression in Late Life

Anti-Depressant Medications

Antidepressant Medication Mgmt

Psychotropic Medication Use in Dementia

Depression in the Medically Ill

Antidepressant Pharmacology An Overview

Depression & Anxiety in Adolescents

Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

Realities of Depression in Primary Care Setting

A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Objectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS

Efficacy and Acceptability of Pharmacological Treatments for Post- Stroke Depression: A Bayesian Network Meta-Analysis

Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences

MANAGEMENT OF VISCERAL PAIN

Anxiety Disorders.

Uses of the NIH Collaboratory Distributed Research Network

Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Major Depressive Disorder (MDD) in Children under Age 6

Jacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301

Professional Practice Minutes September 7 th, 2016

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018

Volume 4; Number 5 May 2010

Treatment of Anxiety (without benzos)

Common Antidepressant Medications for Adults

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Effective Health Care

TREATING MAJOR DEPRESSIVE DISORDER

Treating Depression in Adults

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

Successes in Regional Collaboration to Achieve the Triple Aim Oregon. Pay for Performance Summit San Francisco March 24, 2014

Treating Chronic Illness in the PCMH Handout - Depression. A. Guidelines. 1. Control of Symptoms:

Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)

Depression in Older Adults. Paul Boulware, MD Arizona Neurological Institute April 22, 2012

Antidepressant Medication Therapy in Primary Care July 25, 2013

Pharmacotherapy of depression

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford

Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database

Hazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke

Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Children s Hospital Of Wisconsin

A new Anatomy of Melancholy: rethinking depression and resilience

Treatment-resistant depression in primary care

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Depression in Pregnancy

ERIC J. NESTLER, MD, PhD

Strategies for Diagnosing and Treating Depressive Disorders in Primary Care

Depression. University of Illinois at Chicago College of Nursing

Treating Depression in Disadvantaged Women: What is the evidence?

Tuning Epidemiological Study Design Methods for Exploratory Data Analysis in Real World Data

Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression

The Emperor s New Drugs: Medication and Placebo in the Treatment of Depression

Disclosure Information

Focusing on Depression in the Community. Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Major Depressive Disorder (MDD) in Children under Age 6

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

Antidepressants. BMF 83 - Antidepressants

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Psychiatric Consultant Role in Collaborative Care Sept 12, 2013

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Treatment of Major Depressive Disorder

Transcription:

Large scale analytics for electronic health records: Lessons from Observational Health Data Science and Informatics (OHDSI) Patrick Ryan, PhD on behalf of OHDSI team 15 November 2016

Odyssey (noun): \oh-d-si\ 1. A long journey full of adventures 2. A series of experiences that give knowledge or understanding to someone http://www.merriam-webster.com/dictionary/odyssey

A caricature of the patient journey Disease Treatment Outcome Conditions Drugs Procedures Measurements Person time Baseline time 0 Follow-up time

Each observational database is just an (incomplete) compilation of patient journeys Person 1 Person 2 Person 3 Person N Conditions Conditions Drugs Conditions Drugs Procedures Conditions Drugs Measurements Procedures Measurements Procedures Drugs Person time Measurements Procedures Person time Measurements Baseline time Follow-up time Person 0 time Baseline time Follow-up time Person 0 time Baseline time Follow-up time 0 Disease Disease Disease Disease Treatment Treatment Treatment Treatment Outcome Outcome Outcome Outcome

Questions asked across the patient journey Which treatment did patients choose after diagnosis? Disease Treatment Outcome Conditions Which Drugs patients chose which treatments? Procedures Measurements How many patients experienced the outcome after treatment? Person time Does one treatment cause the outcome more than an alternative? Does treatment cause outcome? Baseline time What is the probability I will develop the disease? 0 Follow-up time What is the probability I will experience the outcome?

Classifying questions across the patient journey Clinical characterization: What happened to them? What treatment did they choose after diagnosis? Which patients chose which treatments? How many patients experienced the outcome after treatment? Patient-level prediction: What will happen to me? What is the probability that I will develop the disease? What is the probability that I will experience the outcome? Population-level effect estimation: What are the causal effects? Does treatment cause outcome? Does one treatment cause the outcome more than an alternative?

Complementary evidence to inform the patient journey Clinical characterization: What happened to them? observation Patient-level prediction: What will happen to me? inference Population-level effect estimation: What are the causal effects? causal inference

http://ohdsi.org Introducing OHDSI The Observational Health Data Sciences and Informatics (OHDSI) program is a multistakeholder, interdisciplinary collaborative to create open-source solutions that bring out the value of observational health data through large-scale analytics OHDSI has established an international network of researchers and observational health databases with a central coordinating center housed at Columbia University

http://ohdsi.org OHDSI s mission To improve health, by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care.

What is OHDSI s strategy to deliver Methodological research reliable evidence? Develop new approaches to observational data analysis Evaluate the performance of new and existing methods Establish empirically-based scientific best practices Open-source analytics development Design tools for data transformation and standardization Implement statistical methods for large-scale analytics Build interactive visualization for evidence exploration Clinical evidence generation Identify clinically-relevant questions that require real-world evidence Execute research studies by applying scientific best practices through open-source tools across the OHDSI international data network Promote open-science strategies for transparent study design and evidence dissemination

OHDSI community OHDSI Collaborators: >140 researchers in academia, industry, government, health systems >20 countries Multi-disciplinary expertise: epidemiology, statistics, medical informatics, computer science, machine learning, clinical sciences Databases converted to OMOP CDM within OHDSI Community: >50 databases >660 million patients

Standardized clinical data Person Drug One safety common surveillance data Comparative model effectiveness to support Device safety surveillance Health economics multiple use cases Vaccine safety surveillance Quality of care Clinical research Observation_period Specimen Death Visit_occurrence Procedure_occurrence Drug_exposure Device_exposure Condition_occurrence Measurement Note Observation Fact_relationship Standardized health system data Location Payer_plan_period Cost Cohort Cohort_attribute Condition_era Drug_era Dose_era Care_site Provider Standardized health economics Standardized derived elements Standardized meta-data CDM_source Concept Vocabulary Domain Concept_class Concept_relationship Relationship Concept_synonym Concept_ancestor Source_to_concept_map Drug_strength Cohort_definition Attribute_definition Standardized vocabularies

Complementary evidence to inform the patient journey Clinical characterization: What happened to them? observation Patient-level prediction: What will happen to me? inference Population-level effect estimation: What are the causal effects? causal inference

How should patients with major depressive disorder be treated?

How are patients with major depressive disorder ACTUALLY treated? Hripcsak et al, PNAS, 2016

OHDSI participating data partners Code Name Description Size (M) AUSOM Ajou University School of Medicine South Korea; inpatient hospital 2 EHR CCAE MarketScan Commercial Claims and US private-payer claims 119 Encounters CPRD UK Clinical Practice Research Datalink UK; EHR from general practice 11 CUMC Columbia University Medical Center US; inpatient EHR 4 GE GE Centricity US; outpatient EHR 33 INPC Regenstrief Institute, Indiana Network for US; integrated health exchange 15 Patient Care JMDC Japan Medical Data Center Japan; private-payer claims 3 MDCD MarketScan Medicaid Multi-State US; public-payer claims 17 MDCR MarketScan Medicare Supplemental and US; private and public-payer 9 Coordination of Benefits claims OPTUM Optum ClinFormatics US; private-payer claims 40 STRIDE Stanford Translational Research Integrated US; inpatient EHR 2 Database Environment HKU Hong Kong University Hong Kong; EHR 1 Hripcsak et al, PNAS, 2016

Treatment pathway study design >250,000,000 patient records used across OHDSI network >=4 years continuous observation >=3 years continuous treatment from first treatment N=264,841 qualifying patients with depression Hripcsak et al, PNAS, 2016

How are patients with major depressive disorder ACTUALLY treated? Substantial variation in treatment practice across data sources, health systems, geographies, and over time Consistent heterogeneity in treatment choice as no source showed one preferred first-line treatment 11% of depressed patients followed a treatment pathway that was shared with no one else in any of the databases Hripcsak et al, PNAS, 2016

One standardized approach can be applied to multiple clinical areas Type 2 Diabetes Mellitus CCAE Hypertension CUMC Depression MDCD CPRD INPC GE JMDC MDCR OPTUM Hripcsak et al, PNAS, 2016

Complementary evidence to inform the patient journey Clinical characterization: What happened to them? observation Patient-level prediction: What will happen to me? inference Population-level effect estimation: What are the causal effects? causal inference

21

Observational research results in literature 85% of exposure-outcome pairs have p < 0.05 What s going wrong? Observational study bias Publication bias P-hacking 29,982 estimates 11,758 papers 22

Observational research in depression 1,935 estimates 23

What if we considered all outcomes? Duloxetine vs. Sertraline for these 22 outcomes: Acute liver injury Acute myocardial infarction Alopecia Constipation Decreased libido Delirium Diarrhea Fracture Gastrointestinal hemorrhage Hyperprolactinemia Hyponatremia Hypotension Hypothyroidism Insomnia Nausea Open-angle glaucoma Seizure Stroke Suicide and suicidal ideation Tinnitus Ventricular arrhythmia and sudden cardiac death Vertigo 24

What if we consider all treatments? Type Class Treatment Drug Atypical Bupropion Drug Atypical Mirtazapine Procedure ECT Electroconvulsive therapy Procedure Psychotherapy Psychotherapy Drug SARI Trazodone Drug SNRI Desvenlafaxine Drug SNRI duloxetine Drug SNRI venlafaxine Drug SSRI Citalopram Drug SSRI Escitalopram Drug SSRI Fluoxetine Drug SSRI Paroxetine Drug SSRI Sertraline Drug SSRI vilazodone Drug TCA Amitriptyline Drug TCA Doxepin Drug TCA Nortriptyline 25

Large-scale estimation for depression 17 treatments 17 * 16 = 272 comparisons 22 outcomes 272 * 22 = 5,984 effect size estimates 4 databases so far (Truven CCAE, Truven MDCD, Truven MDCR, Optum) 4 * 5,984 = 23,936 estimates NOT DATA MINING - Each analysis following best practice in causal inference 26

Estimates are in line with expectations 11% of exposure-outcome pairs have calibrated p < 0.05 In literature, 85% have p < 0.05 27

OHDSI s recommended best practices for population-level effect estimation Evidence Generation Write and share protocol Open source study code Use validated software Replicate across databases Evidence Evaluation Produce standard diagnostics Include negative controls Create positive controls Calibrate confidence interval and p- value Evidence Dissemination Don t provide only the effect estimate Also share protocol, study code, diagnostics and evaluation Produce evidence at scale 28

Complementary evidence to inform the patient journey Clinical characterization: What happened to them? observation Patient-level prediction: What will happen to me? inference Population-level effect estimation: What are the causal effects? causal inference

Populations can be used to accurately predict outcomes for individuals AMI Diarrhea Hypothyroidism Nausea Stroke CCAE AUC 1.00 0.90 0.80 0.70 0.60 0.50 OPTUM MDCR MDCD

Building the LHC of observational research? 31

Join the journey Discussion / questions / comments ryan@ohdsi.org